| 8.2601 -1.44 (-14.84%) | 08-05 15:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.29 | 1-year : | 16.69 |
| Resists | First : | 12.23 | Second : | 14.29 |
| Pivot price | 8.72  |
|||
| Supports | First : | 5.15 |
Second : | 0.76 |
| MAs | MA(5) : | 9.5 |
MA(20) : | 8.52 |
| MA(100) : | 2.41 |
MA(250) : | 1.79 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 50.2 |
D(3) : | 57.4 |
| RSI | RSI(14): 59.6 |
|||
| 52-week | High : | 12.23 | Low : | 0.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ APM ] has closed above bottom band by 37.4%. Bollinger Bands are 75.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.71 - 9.78 | 9.78 - 9.83 |
| Low: | 8.11 - 8.19 | 8.19 - 8.25 |
| Close: | 8.15 - 8.26 | 8.26 - 8.34 |
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Fri, 07 Aug 2026
Aptorum Group Ltd (APM) Stock News Today - TradingKey
Tue, 28 Jul 2026
Niki BioSolutions (APM) Form 3 names President & COO, no trades reported - Stock Titan
Mon, 27 Jul 2026
Aptorum Group Ltd (APM) Earnings Date & Reports & Earnings News - TradingKey
Fri, 24 Jul 2026
Niki BioSolutions (NIKI) director Laura Philips discloses 6,024-share holding - Stock Titan
Fri, 24 Jul 2026
Niki BioSolutions, Inc. (NIKI) insider reports 1,515,293-share stake - Stock Titan
Mon, 20 Jul 2026
NIKI - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 28.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -6.6 % |
| Return on Equity (ttm) | -10.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -4.35 |
| PEG Ratio | 0 |
| Price to Book value | 0.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|